Council. Fran is a frequent plenary and keynote speaker at international meetings.

Fran is also actively involved in communication of science to non-specialist audiences, especially young people. Fran is Director of the Centre of the Cell, a biomedical science centre for children, educational website and outreach project in East London. There have been more than 190,000 participants in Centre of the Cell activities since opening in September 2009. Fran's science communication work has been recognised by the award of the 2004 EMBO prize for communication in the Life Sciences and the 2005 Royal Society Michael Faraday Prize. In 2017, she was awarded the Cancer Research UK Inspiring Leadership in Research Engagement Prize.
Together with illustrator Mic Rolph, Fran has also produced thirteen science books for children on cell and molecular biology with titles such as Enjoy Your Cells, The Egg and Sperm Raceand You, Me and HIV. These books have been translated into at least twelve foreign languages with over half a million copies sold worldwide.

From 2009-2019 Fran was a non-parliamentary board member of the Parliamentary Office of Science and Technology, POST, and currently serves on CRUK and ERC grant committees. She is a Trustee of the charity Bloodwise. Fran was awarded an OBE in the 2008 Queen’s Birthday Honours list. In 2015 Fran was awarded the honorary degree of Doctor of Science honoris causa by the University of Bristol where she studied as an undergraduate.

Dr. Lengyel performed the University of Chicago's first laparoscopic pelvic and para-aortic lymph node dissection for gynecologic cancer. He also performs radical vaginal trachelectomy (RVT) to preserve fertility in young patients who have cervical cancer.

Dr. Lengyel has been recognized by Chicago magazine as one of the city's "Top Doctors" for ovarian and cervical cancer care. He is also skilled in complex pelvic surgeries for benign gynecologic conditions, such as endometriosis and fistula repairs.

Dr. Lengyel's research laboratory in the Center for Integrative Science focuses on the investigation of new therapies for the treatment of ovarian cancer. His research is funded by the National Institutes of Health (NIH). In addition to clinical and research activities, Dr. Lengyel mentors residents and postdoctoral fellows in the Department of Obstetrics/Gynecology.

of Research Excellence (SPORE) in Ovarian Cancer.

As the Director of UCCCC, Dr. Odunsi oversees all programmatic aspects of cancer at the University of Chicago including the three primary missions of research, patient care, and education. He sets the strategic direction of UCCCC, which emphasizes basic, translational, and clinical research efforts; collaborative cancer discovery and care; outreach to and engagement of the catchment area; and expansion of development opportunities for early career and promising cancer researchers. Dr. Odunsi also continues to treat patients and mentor physicians in the clinic.

and the Multidisciplinary Ovarian Cancer Outcomes Group. Consortia broaden the impact we can all have on ovarian cancer and she is proud to be a part of these multidisciplinary efforts!

gynae medical oncology trials lead, deputy lead for the Newcastle Experimental Cancer Medicines centre (phase 1 unit) and co-lead of the gynae-onc translational team. Dr Drew undertook specialist medical oncology training at the Beatson West of Scotland Cancer Centre, Glasgow and the NCCC. During this time she was awarded a CRUK-funded PhD fellowship investigating the role of PARP inhibitors in Homologous Recombination deficient ovarian cancer. During her PhD she won a Merit award for her research from the American Society of Clinical Oncology (ASCO) and was awarded the Medical Sciences Doctoral Prize (Newcastle university, 2013). She has played a key role in both the pre-clinical and clinical development of the PARP inhibitor rucaparib in ovarian cancer. In the UK she has also led on trials as national CI from first-in-human phase 1 to later phase 3 clinical trials and been active as a member of both the NCRI Ovarian and Endometrial clinical studies sub-groups. Research interests include the targeting DNA repair pathways as treatment for gynaecological cancers and PARP inhibitor resistance.

Steering Committee. He's on the Executive Board of the international Gynecologic Cancer InterGroup and Chair (commencing October 2020). He's also co-founder and Director of the Fields Institute Centre for Mathematical Modeling.

(J. Exp. Med. 1996). PI Nijman has also been a driving force in the development and clinical implementation of vaccines that treat or prevent cancer. In seminal work, he demonstrated that the essential cancer suppressor gene p53 was a tumor-specific antigen recognized by the immune system (J. Exp. Med 1997). He spearheaded an effort to translate this finding from bench to bedside for treatment of patients with ovarian cancer. He performed several innovative clinical trials using long peptide-based therapeutic vaccination against p53 alone, or in combination with immune-modulating agents (Int. J. Cancer 2009 and Clin. Can. Res. 2009). PI Nijman further pioneered the development of a Semlike Forest Virus-based cancer vaccine for treatment of patients with cervical cancer and/or premalignant lesions (e.g. Vaccine. 2010 and Int. J. Cancer 2014). He is co-founder of the biotech company Vicinivax that has just concluded a Phase I trial (EudraCT 2015-004979-74) of this vaccine with promising results. Prof. Nijman was also frontrunner during the clinical implementation of the preventive HPV vaccine in the Netherlands and remains actively involved in the long-term follow-up of this population. At present, Prof. Nijman runs several immunotherapy trials in patients with gynecological malignancies, including HPV vaccines (Clin. Can. Res. 2016 and EudraCT 2015-004979-74) and an innovative lipoplex vaccine for treating patients with ovarian cancer (Nat. Med. 2016). Finally, Prof. Nijman oversees a multidisciplinary group of health care providers, insurance organizations, IT specialists and liaises directly with the ministry of health to ensure optimal and equal cancer care is delivered for patients throughout the Netherlands. This €10 million national initiative is already delivering important changes to improving quality of life for cancer patients and is expected to become even more relevant over the coming years with the clinical advent of targeted (immune)therapies..

a Scientist at the Ottawa Hospital Research Institute-Centre for Cancer Therapeutics, and she is also an Assistant Professor in the Department of Biochemistry, Microbiology and Immunology at the University of Ottawa. Her research is focused on the development of innovative biotherapeutics for cancer treatment. Carolina is also involved in training the next generation of scientists. She is a member of the High Qualified personnel training committee for BioCanRx, a Canadian network that develops cancer biotherapeutics.

Dr. Kotsopoulos directs a wide-range of research initiatives to further our understanding of BRCA-associated breast and ovarian cancer, with the goal of identifying viable strategies that confer substantial risk reduction and improve outcomes. Her studies have demonstrated an important role of hormonal, reproductive and modifiable exposures on BRCA-associated cancer development. This critical work has provided women and healthcare providers with evidence-based management options while contributing to our understanding of the pathogenesis of hereditary cancer.

Additional interests are aimed at identifying prognostic factors for ovarian cancer, a highly fatal disease, and furthering our understanding of how variation in treatment may impact outcomes.

She is also actively involved in the teaching and mentoring of students at the University of Toronto across various stages of their academic careers.

Her research program aims to increase our understanding of the etiology of ovarian cancer in order to improve primary prevention and risk assessment efforts. She also conducts research on the identification of modifiable factors that can improve prognosis and quality of life of ovarian cancer survivors. Her research program is currently funded by grants from the Cancer Research Society and the Canadian Institutes of Health Research.

Centre, and Professor in the Department of Immunology at the University of Toronto. She is also the Director of the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre. Her interests include understanding CD8+ T cell biology and mechanisms that regulate anti-tumor immunity.

the mevalonate signaling pathway that appears to be upregulated in metastatic ovarian cancer cells. Jim has published more than 75 articles on his work on ovarian cancer and his research program is funded by the Canadian Institutes of Health Research, the Cancer Research Society, and the Natural Sciences and Engineering Research Council of Canada.

Professor Tsang is internationally recognized for his translational research program in cell fate regulation in women’s reproductive health, especially in the area of anovulatory infertility and chemoresistant ovarian cancer. His research program has been supported continuously by national competitive grants from MRC/CIHR during the past 37 years. He has contributed over 215 full-length original publications and 21 reviews/book chapters, and holds 4 patents. The success of Dr. Tsang’s research is reflected in the numerous honours and awards he received, including the CFAS Award of Excellence in Reproductive Medicine, the Ottawa Centre for Research and Innovations Research Award, the Ottawa Regional Cancer Foundation Angel Award for cancer research excellence, the J David Grimes Research Career Achievement Award, and the uOttawa Faculty of Medicine Award of Excellence. He was appointed the World Class University Professor of Biomodulation at Seoul National University.

Dr. Tsang is the Co-editor-in-Chief of the Journal of Ovarian Research and Associate Editor of Molecular Carcinogenesis and Journal of Cancer Prevention. He has served on the Editorial Board of Endocrinology, Biology of Reproduction, Reproduction, Clinical and Experimental Reproductive Medicine and Adaptive Medicine, and on various CIHR grant committees. He holds honorary professorships at the Chinese Academy of Sciences, Jinan University, Nanjing Medical University and Taipei Medical University.

Professor Tsang served as co-chairs of the China-Canada Bilateral Program on Reproductive Health and the Canada-Japan Bilateral Program on Women’s Health Research in the promotion of international research partnerships and academic exchanges. He served as President of the Canadian Fertility and Andrology Society and a member of the Board of Directors of the Society for the Study of Reproduction (SSR). He is the Chair of the SSR Golden Anniversary Fundraising Campaign.

molecules / antibodies that enhance oncolytic virus activity. Dr. Diallo has published over 65 manuscripts and is co-inventor on 10 licensed patents. He co-founded Virica Biotech in 2018 and, most recently, Virano Therapeutics in 2021.

Dr. Lum’s team will identify metabolites and metabolic pathways that are can be used as novel targets for cell-based immunotherapy.